From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Phase | Other agent | Disease (pt. No.) | Schedule | Recommended dose & response | Reference |
---|---|---|---|---|---|
I | Â | Advanced hematological neoplasms(16) | Day 1 to 5 of a 21-day cycle | 1000 mg/m2/d | [128] |
I | AZA | Advanced myeloid neoplasms(230 | Days 1-5 of a 28 day cycle | 1000 mg/m2 | [129] |
I | Â | Advanced refractory solid tumors(46) | Days 1-5 of a 21 day cycle | 1000 mg/m2 SD 39% | [127] |
II | Â | relapsed malignant pleural mesothelioma(13) | Days 1-5 of a 21 day cycle | Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma | [122] |
II | Â | Platinum resistant epithelial ovarian tumors(EOC,18) and micropapillary/borderline ovarian tumors(LMP,12) | Days 1-5 of a 21 day cycle with 1000 mg/m2 | EOC: SD 50%, PD25% N/E 25%; LMP: SD 75%, PR8.3%, N/E 16.6% | [130] |